Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01016899 · ClinicalTrials.gov registry record

Electronic Brachytherapy for the Treatment of NMSC

A clinical trial of Squamous Cell Carcinoma and Basal Cell Carcinoma, sponsored by Xoft.

Completed
Registry status
187
Enrollment target
5
Study locations

NCT01016899: Completed study of Squamous Cell Carcinoma and Basal Cell Carcinoma, sponsored by Xoft.

NCT01016899 is a study of Squamous Cell Carcinoma and Basal Cell Carcinoma that has completed, run by Xoft. The registered enrollment target is 187 participants, above the 100-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (87% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01016899, a study of Squamous Cell Carcinoma and Basal Cell Carcinoma, has completed, sponsored by Xoft.

COMPLETED
Registry status
187 participants
Enrollment target
5
Study locations

Study Summary

The objective of this study is to record recurrence in patients treated for nonmelanoma (basal cell and squamous cell carcinomas) skin cancer using the Xoft Axxent Electronic Brachytherapy System. Additional objectives include evaluate the appearance of the treated area in patients treated for nonmelanoma skin cancer using the Xoft Axxent Electronic Brachytherapy System and record the occurrence of radiation therapy related skin changes in patients treated for nonmelanoma skin cancer.

Primary Outcome

Local recurrence

Interventions

  • RADIATION electronic brachytherapy

Study Locations (5)

Arizona

  • Cancer Treatment Services - AZ - Casa Grande
  • Southwest Oncology Centers - Scottsdale

Alabama

  • DCH Cancer Center - Tuscaloosa

California

  • Diablo Valley Oncology and Hematology Medical Group - Pleasant Hill

Tennessee

  • Parkridge Medical Center - Sara Cannon Cancer Center - Chattanooga

Trial Details

FieldValue
Enrollment Target 187 participants
Start Date 2009-08
Est. Completion 2013-08
Xoft

10 total trials

What the finished NCT01016899 record still lists

NCT01016899 is an observational study that tracks outcomes without assigning an intervention. The registered 187 participants enrollment target is mid-sized for trials with a published cap, above the 100-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (87% higher).

The record links to 2 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which electronic brachytherapy is the first listed.

NCT01016899 lists 5 locations in 4 states (Arizona, Alabama, California).

Frequently Asked Questions

What is clinical trial NCT01016899 about?

NCT01016899 is a clinical study titled "Electronic Brachytherapy for the Treatment of NMSC". The objective of this study is to record recurrence in patients treated for nonmelanoma (basal cell and squamous cell carcinomas) skin cancer using the Xoft Axxent Electronic Brachytherapy System. Additional objectives include evaluate the appearance of the treated area in patients treated for nonme...

What is the current status of trial NCT01016899?

This trial is currently completed. The enrollment target is 187 participants. The study started on 2009-08. Estimated completion is 2013-08.

What conditions does trial NCT01016899 study?

This clinical trial studies the following conditions: Squamous Cell Carcinoma, Basal Cell Carcinoma.

What interventions are being tested in trial NCT01016899?

The interventions under investigation include: electronic brachytherapy (RADIATION).

Who is sponsoring clinical trial NCT01016899?

This trial is sponsored by Xoft, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01016899 being conducted?

This trial has 5 study locations across Alabama, Arizona, California, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Squamous Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01016899's enrollment target sits among peer trials

187 6th of 47 higher than 42 of 47 other Squamous Cell Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06153251 · 187 participants · Phase 1

    A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

  • NCT06254898 · 187 participants · NA

    Use of Incentives for Stressful Medical Procedures

  • NCT07062237 · 187 participants · NA

    A Randomized Clinical Trial Comparing Embryo Euploidy Rates Following Ultrashort Versus Standard Abstinence

  • NCT07217574 · 187 participants

    Program in Oncology for Tribal Health Systems.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01016899, the US trial registry maintained by the National Library of Medicine. NCT01016899 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.